Sentences with phrase «small molecule drug development»
Not exact matches
SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.
http://www.flxbio.com/
«Our findings will promote the development of specific small - molecule drugs useful to treat Graves» disease and other dysfunctions of GPHRs.»
Initial results were discouraging: attempts to simply replace the protein therapies with small - molecule drugs that hit the same targets largely failed, says Saeed Fatenejad, a rheumatologist at Pfizer who is responsible for clinical development of tasocitinib.
This small molecule is in clinical trials against cancer and has high specificity and good pharmacological properties, which could warrant its further development as antiviral drug for treatment of pH1N1 virus infection,» Dr. Oxana Denisova says.
In early drug development efforts, Longmore and his colleagues have done some preliminary work looking for small molecules that may inhibit DDR2 binding to collagen.
This will give way to the development of a drug to be used in gene therapy against neurodegenerative diseases based on small molecules which enhance the expression of the gene and / or the use of fragments of the Klotho protein itself.
A division of preclinical innovation will house a $ 44 million set of mostly intramural programs, including small - molecule screening and drug development for rare diseases.
Arguably, the most economical and efficient strategy for development of small molecules with regenerative medicine applications is to use non-mammalian animal models for both target - and phenotype - based drug discovery.
SOUTH PLAINFIELD, NJ — December 6, 2007 — PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small - molecule drugs targeting post-transcriptional control mechanisms, today announced an expanded research collaboration with the Spinal Muscular Atrophy (SMA) Foundation.
RNAi therapeutics, peptides and small molecules, drug candidate progression to clinical development, R&D management.
Determining whether a disease - related protein can react strongly with a small - molecule probe or candidate drug — in a way that alters its function — is often an essential first step in drug development.
Vescor, advised by its scientific founders White and Kimmelman, whose research has shown inhibition of autophagy can dramatically impact tumor growth in pre-clinical models, will develop small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug (IND) enabling studies, and move these into clinical development.
I wish them well on developing (1) an antibody to detect and image glucosepane in animals (2) a small molecule drug or enzyme (catabody) to remove the glucosepane (3) luck in finding a development partner for this hypothetical glucosepane breaker.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small - molecule drugs that target post-transcriptional control processes.
Because LINGO1 has be shown to have a negative impact on neuronal development and survival, inibiting it with a small molecule drug may provide an effective approach for developing a treatment for the severe forms of essential tremor.
Because SLC6A14 is essential for tumour growth yet dispensable for normal development and tissue maintenance, small molecules that block amino acid import through this transporter could be effective and selective anti-cancer agents, particularly as components of rational drug combinations.
By default, that's already the case for small - molecule drugs such as the ones under development at Repligen and Roche.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small - molecule drugs that target post-transcriptional control processes.
The ability to encapsulate small - molecule therapeutic compounds into vaults is critical to their development for drug delivery.
About PTC Therapeutics PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes.
«In our previous work, we found that a drug - like small molecule called JQ1 can prevent the development of heart failure in mouse models when administered at the very onset of the disease.
She has experience in small molecule and large molecule development for both oncology and non-oncology indications and has a strong interest in developing alternative in vitro and in vivo methods to assess safety and efficacy outside of the traditional drug development paradigm.
Rigel Pharmaceuticals, Inc is a clinical - stage drug development company that discovers and develops novel, small - molecule drugs for the treatment of inflammatory / autoimmune diseases, as well as for certain cancers and metabolic diseases.
It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
ACADIA Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
PTC Therapeutics Inc., is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small - molecule drugs that target post-transcriptional control processes.
Tags for this Online Resume: high throughput screening, cell culture, data, assay development, drug discovery, label - free, Biacore, Perkin Elmer, small molecule, hit - to - lead, ion channel, GPCR, enzyme, enzymatic, assay
Tags for this Online Resume: Business Development, CRO Services, Biologics, Small Molecules, Preclinical Drug Development, Drug Discovery, In Vivo efficacy models, Preclinical R&D, ELISA, Cardiovascular, Cellular, Injections, Oncology, Research, Pharmaceutical, Business Development Manager, Cancer, Applications, Automation, Field Applications Scientist, Cell based assays
Accomplishments: * Actively consulting on, discovery and development of Antibody Drug Conjugates (ADCs) * Actively consulting on, small molecules process optimization, scale - up and regulatory aspects * Sepsis diagnostic kits (mAb based) business to Asia for development, manuf.
I am interested in Scientist position for designing and developing novel small molecules, developing new synthetic routes and process optimization, for drug discovery and development.